BeyondSprings Pharma R&D Day: Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications
About The Event
The webinar will feature presentations by Key Opinion Leaders (KOLs) Steven Lin, M.D. (MD Anderson Cancer Center), and Trevor M. Feinstein, M.D. (Piedmont Cancer Institute), who will discuss the current treatment landscape and unmet medical need in treating patients with non-small cell lung cancer (NSCLC), and patients who failed checkpoint inhibitors. Drs. Lin and Feinstein will be available to answer questions following the formal presentations.
Also featured will be a management discussion of BeyondSpring’s pipeline including lead asset Plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA), which is developed as a “pipeline in a drug”.
Plinabulin and G-CSF combination is currently in an NDA stage for prevention of chemotherapy induced neutropenia (CIN), which received breakthrough designation and priority review from FDA (PDUFA date 11/30/2021).
Plinabulin and docetaxel combination is tested in a fully enrolled pivotal Phase 3 global study as a direct anticancer agent in patients with NSCLC; the DUBLIN-3 trial is expected to report data in mid-2021.
As a potent APC (antigen presenting cell) inducer, Plinabulin is further tested in combination immuno-oncology regimens, with promising Phase 1 data in 2nd/3rd line SCLC (ASCO 2021), and just initiated Phase 1 study in 7 cancers which failed checkpoint inhibitors at MD Anderson Cancer Center for 7 cancers to investigate plinabulin’s potential to reverse resistance to immunotherapy.